$870M AMS Acquisition: H.B. Fuller Captures Tissue-Healing Tech Portfolio

Advanced Medical Solutions has long been a pioneer in tissue-repair technologies, with a portfolio spanning surgical sealants and advanced wound care biologics. Now, as H.B. Fuller acquires the company for £659M, the biopharma world is asking: Will this trigger a new race for innovative wound biologics and what does it mean for R&D pipelines?

In a definitive move to pivot into high-growth healthcare markets, H.B. Fuller Co., the US industrial adhesives manufacturer, has agreed to acquire Advanced Medical Solutions Group Plc, a UK-based medtech company specializing in tissue-healing products, for an equity value of £659 million ($870 million). The all-cash offer of £2.85 per share, recommended by AMS's board, represents a 35% premium over the stock's closing price in May 2026 before news of the deal talks first broke. Including AMS's debt, the enterprise value reaches £715 million, underscoring H.B. Fuller's ambition to diversify beyond its traditional industrial adhesives business.

“

Fuller Co., the US industrial adhesives manufacturer, has agreed to acquire Advanced Medical Solutions Group Plc, a UK-based medtech company specializing in tissue-healing products, for an equity value of £659 million ($870 million).

The acquisition was first reported by Bloomberg on June 25, 2026, with an initial near-deal valuation of £628 million, before the final agreement was confirmed later that day at the higher price. The leap from the earlier figure to the final £659 million may reflect last-minute adjustments, possibly to account for outstanding management options or a sweetener to secure board approval. Regardless, the deal marks a decisive entry into the $20 billion global wound care market, which is driven by aging populations, rising chronic disease prevalence, and advancements in surgical procedures.

AMS, founded in 1991 and based in Winsford, UK, generates annual revenues of approximately £126 million. Its portfolio includes cyanoacrylate-based surgical adhesives, alginate wound dressings, and hemostatic agents used in operating rooms and chronic wound clinics worldwide. The company addresses conditions such as diabetic ulcers, surgical incisions, and burns, with a strong R&D pipeline focused on next-generation tissue repair. For AMS shareholders, the acquisition provides a lucrative exit at a significant premium, while the company gains the scale and global distribution of a larger parent, potentially accelerating its penetration into the US market.

For H.B. Fuller, with a market cap of around $4 billion, the deal is one of its largest ever. The company already supplies adhesives for medical device assembly and drug delivery systems, but the AMS purchase brings direct patient-facing products and clinical expertise. Management expects the transaction to be immediately accretive to earnings, with margin expansion as higher-margin medtech revenues offset lower-margin industrial lines. Cross-selling opportunities—for example, combining H.B. Fuller's materials science with AMS's wound care products—are substantial.